Evaluation of gemfibrozil therapy: Predictive response from lipoprotein subfraction analysis

Wayne W. Loney, Bhalchandra J. Kudchodkar, Stephen Weis, Michael B. Clearfield, Jay Shores, Andras G. Lacko

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Subjects with high-density lipoprotein cholesterol (HDL-C) values of less than 47 mg/dL (mean 35.6 ± 5.5 mg/dL) were selected for this study to examine relationships between plasma lipids, lipoprotein components, and the outcome of gemfibrozil therapy. Changes in plasma lipoprotein subfractions were determined to better understand the previously observed variability of the responses in both HDL-C and triglycerides to gemfibrozil. Based on the data collected, an attempt was made to identify pretreatment lipid parameters that may be predictive regarding the efficacy of gemfibrozil therapy. Serum samples were analyzed at the outset and after the conclusion of 12 weeks of gemfibrozil-therapy. Because the HDL-C response to therapy was highly variable, the data from patients were separated into two groups, responders (>20% increase in HDL-C) and nonresponders (<20% increase in HDL-C). The lipid components of lipoprotein subfractions were evaluated using multiple regression analysis yielding predictive models that show the relationship between specific lipoprotein subfractions and the percentage change in HDL-C and posttreatment triglyceride levels. Group classification was then predicted with 78% accuracy using specific lipoprotein subfractions to estimate an individual's percentage change in HDL-C. The major difference between the responder and nonresponder groups was their respective correlations between triglyceride-lowering and changes in HDL-C. In the responder group, there was a significant correlation between the changes in HDL-C and the lowering of triglycerides (r = 0,61, p = 0.03), whereas the nonresponder group showed no such correlation (r = 0.17, p = 0.52). The predictive model also proved to be highly accurate in forecasting the effectiveness of the triglyceride-lowering action of gemfibrozil in this group of patients.

Original languageEnglish
Pages (from-to)301-309
Number of pages9
JournalAmerican Journal of Therapeutics
Volume4
Issue number9-10
StatePublished - 1 Sep 1997

Fingerprint

Gemfibrozil
HDL Cholesterol
Lipoproteins
Triglycerides
Lipids
Therapeutics
Regression Analysis
Serum

Keywords

  • Gemfibrozil therapy
  • HDL cholesterol
  • Lipoprotein subfractions
  • Triglycerides

Cite this

Loney, Wayne W. ; Kudchodkar, Bhalchandra J. ; Weis, Stephen ; Clearfield, Michael B. ; Shores, Jay ; Lacko, Andras G. / Evaluation of gemfibrozil therapy : Predictive response from lipoprotein subfraction analysis. In: American Journal of Therapeutics. 1997 ; Vol. 4, No. 9-10. pp. 301-309.
@article{5a9bb82d552a41e189b5e45f645016dd,
title = "Evaluation of gemfibrozil therapy: Predictive response from lipoprotein subfraction analysis",
abstract = "Subjects with high-density lipoprotein cholesterol (HDL-C) values of less than 47 mg/dL (mean 35.6 ± 5.5 mg/dL) were selected for this study to examine relationships between plasma lipids, lipoprotein components, and the outcome of gemfibrozil therapy. Changes in plasma lipoprotein subfractions were determined to better understand the previously observed variability of the responses in both HDL-C and triglycerides to gemfibrozil. Based on the data collected, an attempt was made to identify pretreatment lipid parameters that may be predictive regarding the efficacy of gemfibrozil therapy. Serum samples were analyzed at the outset and after the conclusion of 12 weeks of gemfibrozil-therapy. Because the HDL-C response to therapy was highly variable, the data from patients were separated into two groups, responders (>20{\%} increase in HDL-C) and nonresponders (<20{\%} increase in HDL-C). The lipid components of lipoprotein subfractions were evaluated using multiple regression analysis yielding predictive models that show the relationship between specific lipoprotein subfractions and the percentage change in HDL-C and posttreatment triglyceride levels. Group classification was then predicted with 78{\%} accuracy using specific lipoprotein subfractions to estimate an individual's percentage change in HDL-C. The major difference between the responder and nonresponder groups was their respective correlations between triglyceride-lowering and changes in HDL-C. In the responder group, there was a significant correlation between the changes in HDL-C and the lowering of triglycerides (r = 0,61, p = 0.03), whereas the nonresponder group showed no such correlation (r = 0.17, p = 0.52). The predictive model also proved to be highly accurate in forecasting the effectiveness of the triglyceride-lowering action of gemfibrozil in this group of patients.",
keywords = "Gemfibrozil therapy, HDL cholesterol, Lipoprotein subfractions, Triglycerides",
author = "Loney, {Wayne W.} and Kudchodkar, {Bhalchandra J.} and Stephen Weis and Clearfield, {Michael B.} and Jay Shores and Lacko, {Andras G.}",
year = "1997",
month = "9",
day = "1",
language = "English",
volume = "4",
pages = "301--309",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "9-10",

}

Evaluation of gemfibrozil therapy : Predictive response from lipoprotein subfraction analysis. / Loney, Wayne W.; Kudchodkar, Bhalchandra J.; Weis, Stephen; Clearfield, Michael B.; Shores, Jay; Lacko, Andras G.

In: American Journal of Therapeutics, Vol. 4, No. 9-10, 01.09.1997, p. 301-309.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of gemfibrozil therapy

T2 - Predictive response from lipoprotein subfraction analysis

AU - Loney, Wayne W.

AU - Kudchodkar, Bhalchandra J.

AU - Weis, Stephen

AU - Clearfield, Michael B.

AU - Shores, Jay

AU - Lacko, Andras G.

PY - 1997/9/1

Y1 - 1997/9/1

N2 - Subjects with high-density lipoprotein cholesterol (HDL-C) values of less than 47 mg/dL (mean 35.6 ± 5.5 mg/dL) were selected for this study to examine relationships between plasma lipids, lipoprotein components, and the outcome of gemfibrozil therapy. Changes in plasma lipoprotein subfractions were determined to better understand the previously observed variability of the responses in both HDL-C and triglycerides to gemfibrozil. Based on the data collected, an attempt was made to identify pretreatment lipid parameters that may be predictive regarding the efficacy of gemfibrozil therapy. Serum samples were analyzed at the outset and after the conclusion of 12 weeks of gemfibrozil-therapy. Because the HDL-C response to therapy was highly variable, the data from patients were separated into two groups, responders (>20% increase in HDL-C) and nonresponders (<20% increase in HDL-C). The lipid components of lipoprotein subfractions were evaluated using multiple regression analysis yielding predictive models that show the relationship between specific lipoprotein subfractions and the percentage change in HDL-C and posttreatment triglyceride levels. Group classification was then predicted with 78% accuracy using specific lipoprotein subfractions to estimate an individual's percentage change in HDL-C. The major difference between the responder and nonresponder groups was their respective correlations between triglyceride-lowering and changes in HDL-C. In the responder group, there was a significant correlation between the changes in HDL-C and the lowering of triglycerides (r = 0,61, p = 0.03), whereas the nonresponder group showed no such correlation (r = 0.17, p = 0.52). The predictive model also proved to be highly accurate in forecasting the effectiveness of the triglyceride-lowering action of gemfibrozil in this group of patients.

AB - Subjects with high-density lipoprotein cholesterol (HDL-C) values of less than 47 mg/dL (mean 35.6 ± 5.5 mg/dL) were selected for this study to examine relationships between plasma lipids, lipoprotein components, and the outcome of gemfibrozil therapy. Changes in plasma lipoprotein subfractions were determined to better understand the previously observed variability of the responses in both HDL-C and triglycerides to gemfibrozil. Based on the data collected, an attempt was made to identify pretreatment lipid parameters that may be predictive regarding the efficacy of gemfibrozil therapy. Serum samples were analyzed at the outset and after the conclusion of 12 weeks of gemfibrozil-therapy. Because the HDL-C response to therapy was highly variable, the data from patients were separated into two groups, responders (>20% increase in HDL-C) and nonresponders (<20% increase in HDL-C). The lipid components of lipoprotein subfractions were evaluated using multiple regression analysis yielding predictive models that show the relationship between specific lipoprotein subfractions and the percentage change in HDL-C and posttreatment triglyceride levels. Group classification was then predicted with 78% accuracy using specific lipoprotein subfractions to estimate an individual's percentage change in HDL-C. The major difference between the responder and nonresponder groups was their respective correlations between triglyceride-lowering and changes in HDL-C. In the responder group, there was a significant correlation between the changes in HDL-C and the lowering of triglycerides (r = 0,61, p = 0.03), whereas the nonresponder group showed no such correlation (r = 0.17, p = 0.52). The predictive model also proved to be highly accurate in forecasting the effectiveness of the triglyceride-lowering action of gemfibrozil in this group of patients.

KW - Gemfibrozil therapy

KW - HDL cholesterol

KW - Lipoprotein subfractions

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=0030763267&partnerID=8YFLogxK

M3 - Article

C2 - 10423623

AN - SCOPUS:0030763267

VL - 4

SP - 301

EP - 309

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 9-10

ER -